Citations

Clear

1011 citation(s) found for "Barry, WT".

Correction for Evans et al., “Informing Antibiotic Treatment Decisions: Evaluating Rapid Molecular Diagnostics To Identify Susceptibility and Resistance to Carbapenems against Acinetobacter spp. in PRIMERS III”
Hujer, Andrea M. , Jiang, Hongyu , Hill, Carol , Hujer, Kristine M., Mediavilla, José R. , Tran, Thuy Tien T., Higgins, Paul G. , Kreiswirth, Barry N. , Patel, Robin , Chen, Liang , Sampath, Rangarajan , Marzan, Christine, Fowler, Vance G. , Chambers, Henry F. , Evans, Scott , Manca, Claudia , Domitrovic, Tatiana , Seifert, Harald , Kreiswirth, Barry N , Jacobs, Michael R. , Chen, Liang , Hall, Thomas A. , Fowler, Vance G. , Bonomo, Robert A. , Patel, Robin , Evans, Scott R

Mayo Clinic

Journal of Clinical Microbiology | May 23, 2017 | Volume: 55 | Issue: 6 | Pages: 1970-1970

10.1128/jcm.00525-17 | PMID 28536161 Get It

An endpoint associated with clinical benefit after initial treatment of chronic graft-versus-host disease
Martin, Paul J. , Storer, Barry E. , Inamoto, Yoshihiro , Carpenter, Paul A. , Pidala, Joseph, Palmer, Jeanne , Arora, Mukta , Jagasia, Madan , Arai, Sally , Lee, Stephanie J. , Flowers, Mary E.D. , Cutler, Corey S. , Lee, Stephanie J

Mayo Clinic

Blood | May 11, 2017 | Volume: 130 | Issue: 3 | Pages: 360-367

10.1182/blood-2017-03-775767 | PMID 28495794 Get It

Key Points Complete or partial response at 1 year without secondary systemic treatment provides clinical benefit in patients with chronic GVHD. Success defined by this endpoint is currently observed in fewer than 20% of patients after initial systemic treatment of chronic GVHD.
Cryo-EM structure of human adenovirus D26 reveals the conservation of structural organization among human adenoviruses
Yu, Xiaodi , Campbell, Melody G. , Barry, Mary E., Asturias, Francisco J. , Barry, Michael A. , Reddy, Vijay , Veesler, David , Barry, Michael A , Campbell, Melody G

Mayo Clinic

Science Advances | May 11, 2017 | Volume: 3 | Issue: 5 | Pages: No page available

10.1126/sciadv.1602670 | PMID 28508067 Get It

Near-atomic resolution structure of species-D adenovirus 26 (HAdV-D26) reveals structural conservation among human adenoviruses.
Executive summary of the SCAI/HFSA clinical expert consensus document on the use of invasive hemodynamics for the diagnosis and management of cardiovascular disease
Sorajja, Paul , Borlaug, Barry A. , Dimas, V. Vivian , Forfia, Paul R. , Givertz, Michael M., Kapur, Navin K. , Naidu, Srihari S. , Sorajja, Paul , Fang, James C. , Givertz, Michael M. , Kern, Morton J. , Borlaug, Barry A

Mayo Clinic

Catheterization and Cardiovascular Interventions | May 10, 2017 | Volume: 89 | Issue: 7 | Pages: 1294-1299

10.1002/ccd.27036 | PMID 28489324 Get It

SCAI/HFSA clinical expert consensus document on the use of invasive hemodynamics for the diagnosis and management of cardiovascular disease
Sorajja, Paul , Borlaug, Barry A. , Dimas, Vasiliki V., Fang, James C., Forfia, Paul R. , Givertz, Michael M. , Kapur, Navin K. , Naidu, Srihari S. , Dimas, V. Vivian , Sorajja, Paul , Dimas, Vasiliki V., Kern, Morton J. , Borlaug, Barry A

Mayo Clinic

Catheterization and Cardiovascular Interventions | May 10, 2017 | Volume: 89 | Issue: 7 | Pages: No page available

10.1002/ccd.26888 | PMID 28489331 Get It

The National Living Donor Assistance Center perspective on barriers to the use of federal travel grants for living donors
Mathur, Amit K. , Ojo, Akinolu, Merion, Robert M. , Hong, Barry A.

Mayo Clinic

Clinical Transplantation | May 9, 2017 | Volume: 31 | Issue: 7 | Pages: No page available

10.1111/ctr.12984 | PMID 28485106 Get It

AbstractRecent research has identified important barriers that potential living organ donors face in utilizing travel reimbursement funds from the National Living Donor Assistance Center (NLDAC). In this article, we provide clarification and comment on these potential barriers from the NLDAC program perspective. The goal of financial neutrality for living donors requires further action. We discuss recent developments and further steps that may help achieve this goal and ultimately affect the shortage of donor organs.
INDIE-HFpEF (Inorganic Nitrite Delivery to Improve Exercise Capacity in Heart Failure With Preserved Ejection Fraction)
Reddy, Yogesh N.V. , Shah, Sanjiv J. , LeWinter, Martin M. , Semigran, Marc J., Dávila‐Román, Víctor G. , Anstrom, Kevin J. , Redfield, Margaret M. , Borlaug, Barry A. , LeWinter, Martin, Semigran, Marc, Davila-Roman, Victor G, Anstrom, Kevin, Hernandez, Adrian, Lewis, Gregory D. , Shah, Sanjiv J , Hernandez, Adrian F. , Braunwald, Eugene , Nishimura, Rick , Borlaug, Barry A

Mayo Clinic

Circulation: Heart Failure | May 6, 2017 | Volume: 10 | Issue: 5 | Pages: No page available

10.1161/circheartfailure.117.003862 | PMID 28476756 Get It

Approximately half of patients with heart failure have preserved ejection fraction. There is no proven treatment that improves outcome. The pathophysiology of heart failure with preserved ejection fraction is complex and includes left ventricular systolic and diastolic dysfunction, pulmonary vascular disease, endothelial dysfunction, and peripheral abnormalities. Multiple lines of evidence point to impaired nitric oxide (NO)-cGMP bioavailability as playing a central role in each of these abnormalities. In contrast to traditional organic nitrate therapies, an alternative strategy to restore NO-cGMP signaling is via inorganic nitrite. Inorganic nitrite, previously considered to be an inert byproduct of NO metabolism, functions as an important in vivo reservoir for NO generation, particularly under hypoxic and acidosis conditions. As such, inorganic nitrite becomes most active at times of greater need for NO signaling, as during exercise when left ventricular filling pressures and pulmonary artery pressures increase. Herein, we present the rationale and design for the INDIE-HFpEF trial (Inorganic Nitrite Delivery to Improve Exercise Capacity in Heart Failure with Preserved Ejection Fraction), which is a multicenter, randomized, double-blind, placebo-controlled cross-over study assessing the effect of inhaled inorganic nitrite on peak exercise capacity, conducted in the National Heart, Lung, and Blood Institute–sponsored Heart Failure Clinical Research Network. Clinical Trial Registration URL: http://www.clinicaltrials.gov . Unique identifier: NCT02742129.
Alcohol abstinence ameliorates the dysregulated immune profiles in patients with alcoholic hepatitis: A prospective observational study
Li, Wei , Amet, Tohti, Xing, Yanyan , Liangpunsakul, Suthat , Puri, Puneet , Kamath, Patrick S. , Shah, Vijay H. , Katz, Barry P., Radaeva, Svetlana , Crabb, David W. , Chalasani, Naga , Yu, Qigui , Yang, Dennis J. , Sanyal, Arun J. , Li, Wei

Mayo Clinic

Hepatology | May 3, 2017 | Volume: 66 | Issue: 2 | Pages: 575-590

10.1002/hep.29242 | PMID 28466561 Get It

Alcoholic hepatitis (AH) develops in only a small proportion of heavy drinkers. To better understand the mechanisms underlying this disparity, we conducted a study to define the relationship between AH development and dysregulated immune responses that might be ameliorated by alcohol abstinence. Sixty‐eight AH patients, 65 heavy drinking controls without liver disease (HDC), and 20 healthy controls were enrolled and followed up to 12 months. At baseline, HDC and healthy controls had no significant differences in their plasma levels of 38 inflammatory cytokines/chemokines measured using multiplex immunoassays. However, compared to HDC, AH patients had higher baseline levels of 11 cytokines/chemokines (tumor necrosis factor alpha, interleukin 6 [IL‐6], IL‐8, interferon gamma–induced protein 10, IL‐4, IL‐9, IL‐10, fibroblast growth factor 2, IL‐7, IL‐15, and transforming growth factor alpha) but lower levels of the anti‐inflammatory macrophage‐derived chemokine. AH patients also had more activated yet dysfunctional immune cells as monocytes, T cells, and B cells expressed higher levels of cluster of differentiation 38 (CD38) and CD69 but low levels of human leukocyte antigen DR, CD80, and CD86 at baseline. In addition, CD4 T cells produced less interferon‐gamma in response to T‐cell stimulation. Up‐regulated IL‐6, IL‐8, CD38, and CD69 and down‐regulated macrophage‐derived chemokine, human leukocyte antigen DR, CD86, and CD80 correlated positively and negatively, respectively, with disease severity. Longitudinal analysis indicated that levels of IL‐6, IL‐8, CD38, and CD69 were reduced, whereas levels of macrophage‐derived chemokine, human leukocyte antigen DR, CD80, and CD86 were increased in abstinent AH patients. All of the cellular immune abnormalities were reversed by day 360 in abstinent AH patients; however, plasma levels of tumor necrosis factor alpha, IL‐8, IL‐10, fibroblast growth factor 2, and IL‐7 remained higher. Conclusion: AH patients were in a highly immune‐dysregulated state, whereas HDC showed little evidence of immune activation; alcohol abstinence reversed most, but not all, of the immunological abnormalities. (Hepatology 2017;66:575–590).
Percutaneous Pericardial Resection
Borlaug, Barry A. , Carter, Rickey E. , Melenovský, Vojtěch , Gaba, Prakriti , Killu, Ammar M. , Naksuk, Niyada , Lerman, Lilach O. , Asirvatham, Samuel J. , Killu, Ammar, Lerman, Lilach, DeSimone, Christopher V. , Asirvatham, Samuel J , Borlaug, Barry A , Carter, Rickey E , Melenovský, Vojtěch

Mayo Clinic

Circulation: Heart Failure | April 11, 2017 | Volume: 10 | Issue: 4 | Pages: No page available

10.1161/circheartfailure.116.003612 | PMID 28396500 Get It

Background— People with heart failure and preserved ejection fraction develop increases in left ventricular (LV) end-diastolic pressures during exercise that contribute to dyspnea. In normal open-chest animal preparations, the pericardium restrains LV filling when central blood volume increases. We hypothesized that resection of the pericardium using a minimally invasive epicardial approach would mitigate the increase in LV end-diastolic pressure that develops during volume loading in normal and diseased hearts with the chest intact. Methods and Results— Invasive hemodynamic assessment was performed at baseline and after saline load before and after pericardial resection in normal canines with open (n=3) and closed chest (n=5) and in a pig model with features of human heart failure and preserved ejection fraction with sternum intact (n=4). In closed-chest animals, pericardiotomy was performed using a novel subxiphoid procedure. In both experimental preparations of normal dogs, pericardiotomy blunted the increase in LV end-diastolic pressure with saline infusion, while enhancing the saline-mediated increase in LV end-diastolic volume. With chest intact in the pig model, percutaneous pericardial resection again blunted the increase in LV end-diastolic pressure secondary to volume expansion (+4±3 versus +13±5 mm Hg; P =0.014), while enhancing the saline-mediated increase in LV end-diastolic volume (+17±1 versus +10±2 mL; P =0.016). Conclusions— This proof of concept study demonstrates that pericardial resection through a minimally invasive percutaneous approach mitigates the elevation in LV filling pressures with volume loading in both normal animals and a pig model with diastolic dysfunction. Further study is warranted to determine whether this method is safe and produces similar acute and chronic hemodynamic benefits in people with heart failure and preserved ejection fraction.